Salute H24

NIH Researchers Estimate 17% of Food-Allergic Children Have Sesame Allergy

Investigators at the National Institutes of Health have found that sesame allergy is common among children with other food allergies, occurring in an estimated 17% of this population. In addition, the scientists have found that sesame antibody testing — whose utility has been controversial — accurately predicts whether a child with food allergy is allergic to sesame. The research was published on Oct. 28 in the journal Pediatric Allergy and Immunology.

Using Virtual Reality to Improve Health

Virtual reality—often referred to as “VR”—used to be science fiction. Today, it’s everywhere. All you need is a smartphone and a headset to immerse yourself in 3-D virtual worlds or games. This booming technology may also be useful for health care and research.

Teen e-cigarette use doubles since 2017

Data from the 2019 Monitoring the Future Survey of eighth, 10th and 12th graders show alarmingly high rates of e-cigarette use compared to just a year ago, with rates doubling in the past two years. University of Michigan, Ann Arbor, scientists who coordinate and evaluate the survey released the data early to The New England Journal of Medicine (NEJM) to notify public health officials working to reduce vaping by teens. The survey is funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

Chinese study reveals underuse of lifesaving drugs after heart attacks

Many heart attack patients in China fail to receive beta-blockers which could prevent another event and save their life. The research is presented at the 30^th Great Wall International Congress of Cardiology (GW-ICC).

Ovarian Cancer: More Women Benefit from Maintenance Combined Targeted Therapy #ESMO19

New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation. According to late breaking results of the PAOLA-1/ENGOT-ov25 trial, this approach extends progression free survival in patients with advanced ovarian cancer. (1) 

One in two patients with metastatic melanoma alive after five years with combination immunotherapy #ESMO19

One in two patients with metastatic melanoma is alivewith combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019 in Barcelona, Spain. ⁽¹⁾ “In the past, metastatic melanoma was regarded as untreatable,” said study author Prof James Larkin, Royal Marsden NHS Foundation Trust,London, UK. “Oncologists considered melanoma different to other cancers –it couldn’t be treated once it had spread. Traditional chemotherapy never really worked well.

100 abstracts and 15 late-breaking abstracts include a Roche medicine. A broad oncology portfolio #ESMO19

Roche today announced that results from a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress, taking place from 27 September - 1 October in Barcelona, Spain.

Large meta-analysis links IVF to higher gestational diabetes risk #EASD2019

Women who give birth to singleton babies following assisted reproductive technologies including vitro fertilisation (IVF) are at greater risk of developing gestational diabetes than those who conceive naturally, according to a meta-analysis involving over almost 2 million singleton pregnancies.

 

FDA approves Rybelsus* (semaglutide), first oral GLP-1 treatment for type 2 diabetes

The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.

Early signs of adult diabetes are visible in children as young as 8 years old #EASD2019

Early signs of adulthood type 2 diabetes can be seen in children as young as 8 years old, decades before it is likely to be diagnosed, according to a new genetic study being presented at this year’s European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Spain (16–20 September).